HIGH
Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), Injection for IV use, 50 mL syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0156-02.
Labeling: Incorrect or Missing Lot and/or Exp Date
STAQ Pharma
Labeling: Incorrect
HIGH
RC Outsourcing Recalls Bevacizumab Syringes Over Sterility Concerns
RC Outsourcing LLC recalled 2,669 syringes of Bevacizumab on September 22, 2025. The recall stems from a lack of assurance of sterility, raising significant health risks. Healthcare providers and consumers should stop using the product immediately.
Quick Facts at a Glance
- Recall Date
- September 22, 2025
- Hazard Level
- HIGH
- Brand
- RC Outsourcing
- Category
- Health & Personal Care
- Sold At
- Multiple Retailers
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL
Hazard Information
Lack of assurance of sterility.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact RC Outsourcing, LLC or your healthcare provider for guidance. Notification method: Letter
Product Details
The recalled product is Bevacizumab 1.75 mg/0.07 mL in 0.25 mL syringes. The syringes were distributed nationwide in the U.S. and are for hospital or office use only.
The Hazard
The recall is due to a lack of assurance of sterility, which poses a high risk of infection to patients. This is classified as a Class II recall by the FDA.
Reported Incidents
No specific injuries or incidents have been reported related to this recall. However, the potential for serious health complications exists due to the sterility issue.
What to Do
Stop using the recalled product immediately. Contact RC Outsourcing LLC or your healthcare provider for guidance on the next steps.
Contact Information
For more information, contact RC Outsourcing LLC at their official website or through the provided FDA link.
Key Facts
- Recall date: September 22, 2025
- Report date: October 15, 2025
- Quantity recalled: 2,669 syringes
- Class II recall due to sterility concerns
- For hospital/office use only
Get Alerts for Health & Personal Care Recalls
Get notified about recalls in categories you care about.
Safety Assessment
Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER
Product Classification
Product TypeIntravitreal Injection
Sold At
Multiple Retailers
Product Details
Brand
Model Numbers
Lot # 20250708-768A26
20250715-944DF2
20250722-55C603
20250722-5DC113
Affected States
ALL
Report Date
October 15, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE
Related Recalls
HIGH
Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 60687-695-01 - Carton NDC [60687-695-11- Unit Dose]
CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
SUCRALFATE
CGMP Deviations:
HIGH
Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0104-05.
Labeling: Incorrect or Missing Lot and/or Exp Date
STAQ Pharma
Labeling: Incorrect